Company Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-16 EST			5-day change	1st Jan Change
50.00 ^USD	-0.52%		-2.17%	+0.60%

01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
12-22	Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing	MT

Business description: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Number of employees: 674

Sales by Activity: Supernus Pharmaceuticals, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Pharmaceuticals	520M	580M	667M	608M	662M

See all business segments

Geographical breakdown of sales: Supernus Pharmaceuticals, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	520M	580M	667M	608M	662M

See all geographic segments

Executive Committee: Supernus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Jack Khattar CEO	Chief Executive Officer	64	2005-12-21
Timothy Dec DFI	Director of Finance/CFO	67	2021-08-22
Frank Mottola CTO	Chief Tech/Sci/R&D Officer	54	2016-12-31
Jonathan Rubin CTO	Chief Tech/Sci/R&D Officer	64	2020-12-31
Padmanabh P. Bhatt CTO	Chief Tech/Sci/R&D Officer	68	2012-04-24

See SUPERNUS PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Supernus Pharmaceuticals, Inc.

Director	Title	Age	Since
Jack Khattar BRD	Director/Board Member	64	2005-12-21
Charles Newhall CHM	Chairman	80	2016-08-09
Frederick Hudson BRD	Director/Board Member	80	2010-11-15
Georges Gemayel BRD	Director/Board Member	65	2015-03-22
Carrolee Barlow BRD	Director/Board Member	62	2018-06-26
Bethany Sensenig BRD	Director/Board Member	50	2023-08-20

Composition of the Board of Directors

Shareholders: Supernus Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.56 %	8,162,588	14.56 %	406 M $
Vanguard Fiduciary Trust Co. 10.78 %	6,044,750	10.78 %	300 M $
DFA Australia Ltd. 5.168 %	2,897,931	5.168 %	144 M $
Armistice Capital LLC 5.058 %	2,836,000	5.058 %	141 M $
Nomura Investment Management Business Trust 4.515 %	2,531,537	4.515 %	126 M $

List of SUPERNUS PHARMACEUTICALS, INC. shareholders

Company details: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue

20850, Rockville

+301 838 2500

http://www.supernus.com

address Supernus Pharmaceuticals, Inc.(SUPN)

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SUPERNUS PHARMACEUTICALS, INC.	-0.52%	-2.17%	+32.49%	+24.25%	2.87B
MERCK KGAA	-0.69%	-1.64%	-9.08%	-31.69%	65.56B
KYOWA KIRIN CO., LTD.	+0.18%	+0.02%	+12.54%	-11.51%	8.5B
HALOZYME THERAPEUTICS, INC.	-0.85%	-1.74%	+29.95%	+35.20%	8.37B
SK BIOPHARMACEUTICALS CO., LTD.	+0.67%	-3.76%	+9.75%	+66.30%	6.4B
YUHAN CORPORATION	-0.28%	-4.77%	-19.48%	+113.76%	5.47B
INDIVIOR PLC	-1.05%	-8.18%	+179.31%	+32.82%	4.06B
BETTA PHARMACEUTICALS CO., LTD.	-0.70%	-2.10%	-10.96%	-17.61%	3.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.89%	+3.79%	+56.78%	+44.94%	2.77B
Average	-0.16%	-1.40%	+31.25%	+28.50%	11.89B
Weighted average by Cap.	-0.52%	+0.08%	+6.20%	-5.24%